Healthcare: Pfizer Takes Aim At Regeneron, And UnitedHealth's Earnings Update

26:15
 
Share
 

Manage episode 244537951 series 2394758
By The Motley Fool. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Pfizer's latest phase 3 trial results put its promising eczema drug on a path to challenge Regeneron and Sanofi's $2 billion-per-year drug, Dupixent. Also, how Regenxbio and Adverum Biotechnologies hope to change how a we treat a common cause of vision loss in seniors, and why United Healthcare's latest quarterly results sent shares soaring.

Check out more of our content here:

1509 episodes